Google
IMNM — IMMUNOME INC (Healthcare >> Biotechnology)
IMNM FAQ
What is IMNM's ROE?
IMMUNOME INC reports a Return on Equity (ROE) of -38.15%.
What is IMNM's dividend yield?
IMMUNOME INC offers a dividend yield of 0.00%.
What is IMNM's Deepscope Quality Score?
Deepscope rates IMNM's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IMNM?
Deepscope's AI Timing Score for IMNM is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IMNM belong to?
IMMUNOME INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 18.38
Price
0.02
(0.11%)
Day Change
|
|
|---|
IMNM, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 18.38 |
| PBV / Sector |
3.53 / 4.91
|
| Earning Per Share | -1.99 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
25.10 M
GREAT
|
| Average 1W Daily Value |
25.71 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:00 |
| Symbol | IMNM |
| Name | IMMUNOME INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 113.25 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,079.28 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 18702 North Creek Parkway, Bothell, WA, United States, 98011
Phone: 425 939 7410
Website: https://immunome.com
Employees: 206
Sector: Healthcare >> Biotechnology
Description: Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
